尿酸作用機(jī)制 - Medchemexpress - MCE中國(guó)

1、Product Data SheetUric acidCat. No.: HY-B2130CAS No.: 69-93-2分式: CHNO分量: 168.11作靶點(diǎn): Endogenous Metabolite; Reactive Oxygen Species作通路: Metabolic Enzyme/Protease; Immunology/Inflammation; NF-B儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) 1M NaOH : 7.14 mg/mL (42.47 m

2、M; Need ultrasonic)DMSO : 1 mg/mL (insoluble or slightly soluble)H2O : 0.1 mg/mL (insoluble)SolventMass1 mg 5 mg 10 mgConcentration制備儲(chǔ)備液1 mM 5.9485 mL 29.7424 mL 59.4849 mL5 mM 1.1897 mL 5.9485 mL 11.8970 mL10 mM 0.5948 mL 2.9742 mL 5.9485 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的

3、保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)內(nèi)使，-20C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)內(nèi)使。BIOLOGICAL ACTIVITY物活性 Uric acid種內(nèi) 性抗氧化劑，可 除活性氧類化合物 (ROS)，包括單線態(tài)氧，氧由基和過氧亞硝酸鹽。IC & Target Human Endogenous Metabolite體外研究Uric acid is an endogenous antioxidant that scavenges reactive oxygen species (ROS) including singlet oxygen

4、,oxygen radicals, and peroxynitrite. Incubation with indomethacin significantly increases malondialdehyde (MDA)levels in Caco-2 cells compare to those not treated indomethacin. Incubation with both indomethacin and Uric acidsignificantly decreases MDA levels compare to those grown in the presence of

5、 indomethacin alone. Co-treatment ofcells with indomethacin and Uric acid significantly decreases ROS levels compare to those in cells incubated withindomethacin alone. Cell viability in Caco-2 cells treated with both indomethacin and Uric acid is higher than that inPage 1 of 2 www.MedChemEcells tre

6、ated with indomethacin alone. Uric acid has a protective effect on indomethacin-induced intestinal cellchanges through its antioxidant activity1.體內(nèi)研究 When mice treated with indomethacin are concurrently administered Uric acid orally, ulcer areas are significantlyreduced, in a Uric acid dose-dependen

7、t manner. Indomethacin increases the ratio of crypt depth to villous height inthe ileum, while the ratio is significantly lower when mice are concurrently administered Uric acid orally.Administration of indomethacin also increases the histopathological score of tissue damage in the small intestine,w

8、hile mice concurrently administered Uric acid orally has a significantly lower histopathological score. The ileal levelsof malondialdehyde (MDA) in indomethacin-induced enteropathy model mice orally administered Uric acid are alsosignificantly lower than the levels in mice administered indomethacin

9、alone1.PROTOCOLCell Assay 1 Human colon carcinoma cells (Caco-2) are used and grown in Eagles minimum essential medium supplementedwith 10% FBS, 1% non-essential amino acid mixture, and 1% Pen-Strep at 37C in a humidified atmosphere with 5%CO2. Caco-2 cells are incubated with indomethacin in the pre

10、sence or absence of Uric acid for 24 or 48 hours1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal To evaluate the effect of oral administration of Uric acid on NSAID-induced enteropathy, mice are given Uric acid (Administration 1 2.5, 10, 25, 100

11、, or 250 mg/kg body weight) suspended in 0.5% carboxymethyl cellulose orally at 30 minutes before,and 12 hours after indomethacin or vehicle treatment. To evaluate the effect of intraperitoneal administration ofinosinic acid plus potassium oxonate on NSAID-induced enteropathy, mice are given inosini

12、c acid (500 mg/kg bodyweight) plus potassium oxonate (250 mg/kg body weight) 24 intraperitoneally at 30 minutes before, and 12 hoursafter indomethacin or vehicle treatment1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Yasutake Y, et al. Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. J Gastroenterol Hepatol. 2017Nov;32(11):1839-1845.McePdfHeightCaution: Product has n